Failures in reproductive Health Policy

Citation for published version:
Sher, J, Frank, J, Doi, L & de Caestecker, L 2018, 'Failures in reproductive Health Policy: Overcoming the consequences and causes of inaction', Journal of Public Health, pp. 1-7.
https://doi.org/10.1093/pubmed/fdy131

Digital Object Identifier (DOI):
10.1093/pubmed/fdy131

Link:
Link to publication record in Edinburgh Research Explorer

Document Version:
Publisher's PDF, also known as Version of record

Published in:
Journal of Public Health

General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.
Perspectives
Failures in reproductive health policy: overcoming the consequences and causes of inaction

Jonathan Sher¹, John W. Frank², Lawrence Doi², Linda de Caestecker³

¹Independent Consultant on Preconception Health, Edinburgh, UK
²Scottish Collaboration for Public Health Research and Policy, Usher Institute of Population Health Sciences and Informatics, University of Edinburgh, Edinburgh, UK
³Director of Public Health, NHS Greater Glasgow and Clyde, Glasgow, UK

Address correspondence to Jonathan Sher, E-mail: jonathan@deltaforce.net

ABSTRACT

It is assumed that long-established research findings and internationally accepted evidence should, and will, be translated into policy and practice. Knowledge about what prevents harm and promotes health has, in fact, guided and resulted in numerous beneficial public health actions. However, such is not always the case. The authors examine three notable, and unwelcome, exceptions in the UK—all in the field of reproductive health and all focused on the period prior to pregnancy. The three examples of counterproductive inaction discussed are: fortifying flour with Vitamin B9 (folic acid); preventing foetal alcohol spectrum disorders; and reducing risks and better regulating a highly teratogenic medication (valproate). The adverse consequences, as well as the causes, of inaction are analysed for each example. Reasons for optimism, and recommendations for overcoming inaction, are also offered, in particular, greater priority should be accorded to preconception health, education and care.

Keywords evidence-based policy, fetal alcohol spectrum disorders (FASD), folic acid, preconception health, (public) health policy, pregnancy, prevention of birth defects, reproductive health, valproate
of inaction are much more frequent and more profound than acknowledged.

Profiles in procrastination
Case 1: Not fortifying flour with vitamin \(B^9\)
Ironies abound in this example. A total of 80 countries around the world mandate the fortification of flour, or another staple grain, with vitamin \(B^9\) (folic acid)—but not the UK.\(^7\) This is true even though the British Medical Research Council funded the still-lauded, 1991 randomized control trial that provided the scientific foundation for international fortification.\(^8\) Following 2 decades of closely monitored implementation, no country has ever had cause to discontinue mandatory vitamin \(B^9\) food fortification.

The justification for significantly increasing women’s blood folate levels prior to conception is beyond scientific doubt. An adequate level of folate (primarily from folic acid) prevents more than two-thirds of neural tube defects (NTDs). But, the preventative benefit is achieved only if that higher level is reached during the months before conception and at least the first month of pregnancy (when the neural tube forms).\(^9\) NTDs include not only spina bifida and four forms of disordered brain development among live births, but also lead to miscarriages, voluntary terminations, stillbirths and infant deaths.

Only a minority of prospective mothers have adequate folate levels at the start of their pregnancy—almost always the result of an extended, daily, individual regimen of vitamin \(B^9\) (folic acid) supplementation.\(^10\) Among women of childbearing potential, the prevention benefits are realized less frequently by those with low socioeconomic status. This inequality is exacerbated by the fact that roughly half of all UK pregnancies are unintended or mistimed. Twenty years of actively promoting ‘voluntary supplementation’ has not succeeded.\(^11\)

For the sake of both primary prevention and reducing inequalities, the solution is to mandate vitamin \(B^9\) fortification of all wheat (but not wholegrain) flour and/or other grains. This still allows consumers to choose non-fortified products and voluntary supplementation, if they prefer.

The lead researcher for the original 1991 RCT is Dr Nicholas Wald, later honoured with a knighthood for his contributions to global public health. And yet, Professor Sir Nicholas’ advice to mandate fortification of flour with vitamin \(B^9\)—as a matter of urgency—has been ignored for more than 25 years within the UK.\(^12\)

Major new research from Wald et al.\(^13\) removes the last medical-minority doubt about folic acid fortification. It reveals that fears of an ‘overdose’ are groundless, as there are no ill effects from ingesting any plausible level of vitamin \(B^9\)—bodies merely eliminate any excess.

Repeatedly, and in great detail, the UK’s Food Standards Agency’s own Scientific Advisory Council on Nutrition (SACN) has examined the evidence on the pros and cons of fortification. It also assessed the evidence from all the countries mandating fortification. Each time, SACN has publicly endorsed adding vitamin \(B^9\) to flour without reservation—but also without success.\(^14\)

The final irony is that the UK has already mandated and implemented the fortification of (non-wholegrain) wheat flour with four health-promoting ingredients—including both vitamin \(B^1\) (thiamine) and \(B^3\) (niacin)—for more than half a century.\(^15\)

Case 2: Minimizing the existence and importance of foetal alcohol harm
Starting with the 18th century Gin Act, UK governments and campaigners have tried to reduce alcohol harm. However, this general aspiration rarely extended to discouraging alcohol consumption during pregnancy. In fact, alcohol was used to offset some gestational symptoms.\(^16,17\)

The term ‘Fetal Alcohol Syndrome’ first appeared in The Lancet in 1973.\(^18\) Following up in Scotland, Dr Forrester Cockburn, Professor of Child Health at Glasgow University/Yorkhill Hospital, co-authored a 1983 article in the ‘British Medical Journal’ on the dozens of FAS cases quickly confirmed locally.\(^19\) The entire topic then virtually disappeared from the medical literature and health policy for more than 2 decades in Scotland/UK.\(^20\)

Over the next 35 years, full-blown FAS came to be understood as constituting only ~10% of cases of the much broader entity, FASD.\(^21\) There is longstanding scientific agreement that alcohol is a teratogenic agent, passing easily through the placenta, un-metabolized by the foetus. Among those affected, the harm typically includes irreversible neurodevelopmental, cognitive and behavioural impairment.\(^22,23\)

Amidst recent attention to ‘Scotland’s unhealthy relationship with alcohol’—including landmark minimum unit pricing legislation implemented in Scotland in 2018—FASD is mentioned only in passing.\(^24,25\) This FASD policy vacuum is especially noteworthy given that women in Scotland and the rest of the UK are equal consumers of alcohol in the heaviest-drinking World Health Organization region.\(^26\) FASD remains a cultural, professional and governmental ‘blind spot’ allowing foetal alcohol harm and its lifelong consequences to continue unabated. Even minimum unit pricing may not solve the problem.\(^27\)
Case 3: Failing to control access to, and gain informed consent about, valproate prescribing for women of reproductive age

French scientists serendipitously discovered in the early 1960s that valproate had anti-seizure properties. The US Food and Drug Administration (FDA) first approved it as an epilepsy medication 40 years ago (1978). The reality was confirmed in the 1980s that valproate was an especially powerful teratogen—with up to 40% of exposures during pregnancy resulting in significant physical and neurodevelopmental birth defects. Thus, the basis for informing, counselling and contraception as needed, while taking valproate (ranging from clearer warnings to better informed consent procedures) and prior to conception (e.g. risk assessments, counselling and contraception as needed, while taking valproate) has long been known.

Across the UK, many women having epilepsy and prescribed valproate have received ‘preconception’ counselling (including switching medications pre-pregnancy). Similarly, no competent doctor would ‘start’ prescribing valproate to a visibly pregnant woman. There are automatic warnings and contraindications built into the prescribing system. Recently, a widespread, clear warning has been issued across the UK against prescribing valproate, for any reason, to women of childbearing potential. And yet, in recent years, 92,000 valproate prescriptions annually have been given to young girls and women of childbearing age, in England alone.

Recent public outcry in France has now reached the European Medicines Agency (EMA). The EMA held its first-ever Public Hearing in September 2017 to address problems and possible solutions related to valproate. In 2018, the EMA, and subsequently the UK Government and Irish legislature, finally recommended significantly stronger measures to reduce exposure to valproate during pregnancy (ranging from clearer warnings to better informed consent procedures) and prior to conception (e.g. risk assessments, counselling and contraception as needed, while taking valproate).

These are welcome steps forward, but they beg the question: Why were not such sensible public health measures implemented over the past 3 decades, since the requisite scientific knowledge was already firmly in place?

The price of passivity

It is one thing to refrain from initiating public health and clinical actions when credible evidence and understanding are sparse or contradictory. But, it is quite another to have had so much certainty for so long, and yet fail to act. Major and enduring damage was done in the UK over the past decades to the thousands of people (both living and dead) who have been affected by preventable NTDs, FASD and exposure to valproate in utero. There is no cure for spina bifida, anencephaly or other NTDs; no one ‘outgrows’ foetal alcohol harm; and, none of the valproate-induced birth defects are fully rectifiable.

Adding insult to injury, ‘secondary effects’ associated with each of these birth defects compromise lives and life chances. For instance, victims can experience stigmatization, bullying, or exclusion from school. Their parents, siblings, family members and carers have also had their work, personal and economic lives radically changed by their responsibilities toward those with FASD, NTDs or foetal valproate harm. Adverse pregnancy outcomes (e.g. miscarriages) also come with a significant human cost.

The high financial/economic burdens associated with NTDs, FASD and valproate-harm have been formally but incompletely estimated—e.g. the familiar reference to ‘million dollar FASD babies’ in Canada. Beyond these tangible burdens on the public purse and the human costs noted above, there is a broader professional and societal price tag for inaction, including loss of confidence in public health policymakers and practitioners, and questioning their commitment to reproductive health and primary prevention.

The causes of inaction

We suggest that prolonged inaction on these pregnancy-related public health measures can best be explained by cultural factors in Scotland and the rest of the UK. ‘Cultural’ in this context refers to the ‘prevailing’ beliefs, values, assumptions, social norms, traditions, language, attitudes and socialization processes that shape collective thinking, reactions and actions.

‘First, the UK’s public policy apparatus operates in a fundamentally reactive, crisis-driven manner—and FASD, NTDs and valproate misuse have not been perceived by the ‘powers that be’ as crises.’ A hallmark of the current era is a recurring series of inquiries to apologize for, and ‘learn lessons’ from, numerous crises—from child sexual abuse to the Grenfell Tower fire—that were predicted, but not prevented. The UK’s cultural definition of ‘heroism’ and ‘leadership’ is deeply rooted in the idea of taking bold actions to deal with an out-of-control crisis.

There is plenty of rhetorical support in favour of primary prevention and preventative spending, but that is neither honoured nor reflected in the actual distribution of human, institutional and financial resources and rewards. Scotland’s respected 2011 Christie Commission on the Future Delivery of Public Services concluded that 40% of all public expenditures were driven by ‘failure demand’, i.e. reacting after the fact when prevention would have been wiser and less
expensive. Due to the combination of austerity and recession—two crisis-provoking events—that percentage has subsequently risen.  

‘Second, there is an abiding cultural discomfort with sexual/reproductive matters; the UK has not fully disentangled itself from a global tendency of not prioritizing things related to pregnancy/parenthood—perhaps because they are considered as “women’s business”.46 This reflects intrinsic sexism and the remnants of a patriarchal society (e.g. the inclination to blame women, rather than empower and support them in relation to their own reproductive goals/lives).

It is neither inevitable, nor a coincidence, that roughly 50% of UK pregnancies are unintended or mistimed—and that nearly one in six pregnancies are terminated (higher in England than Scotland). 47 Most UK babies are conceived in an earlier Member of the UK Parliament (having finally been added uncontroversially to UK baked goods for valproate). For many people, it is challenging to remember that nearly one in six pregnancies are terminated (higher in England than Scotland). 47 Most UK babies are conceived in this context of ambivalence about, and/or lack of preparation for, parenthood. This means fundamental questions frequently go both unasked and unanswered. As a culture, the UK exhibits an extraordinarily ‘lâse faire’ attitude toward preparing and supporting the next generation of mothers and fathers.

‘Third, our three illustrations shine different lights on how language can undermine desirable outcomes.’ Wordings matters in the flour ‘fortification’ debate. ‘Folic acid’ may not have been as good a choice for reassuring policymakers and the public as ‘vitamin B9’. Adding a vitamin to our food sounds more benign than adding an acid. That may help explain why ‘niacin’ (vitamin B3)—rather than the more ominous-sounding chemical name for it, ‘nicotinic acid’—has been added uncontroversially to UK baked goods for half a century.

Valproate also offers a lesson about terminology. Current attempts to alert the public about significant, proven risks of taking valproate during pregnancy often forget that women of childbearing potential are rarely prescribed generic ‘valproate’. Instead, women in Europe perceive themselves as taking one of the 30+ brand-name versions of valproate (from Absenor to Hexaquin). For many people, it is challenging to remember brand names, let alone the active ingredient(s). This represents a crucial and dangerous linguistic disconnect.

‘Fourth, the UK’s relatively non-litigious culture—while a blessing in many respects—may have removed one powerful motivation for implementing these three public health measures.’ Samuel Johnson’s famous 18th century observation—‘Depend upon it, sir, when a man knows he is to be hanged in a fortnight, it concentrates his mind wonderfully.’—may be applicable here today. If the chances of being sued, charged with an offence, publicly shamed or held accountable in other meaningful ways for failing to act are minimal, then the impetus to implement is significantly diminished.

‘Fifth, there continues to be ‘wilful ignorance’ across Scotland and the rest of the UK about the prevalence of FASD, NTD-affected pregnancies and valproate-related birth defects.’ The absence of Scottish/UK epidemiological evidence—and other data about the consequences/costs—of all three problems is a choice, not an inevitability. Ignorance has not been ‘bliss’ for those harmed by this choice.48

### Replacing inaction with accomplishment

If cultural factors best explain why these three public health measures should have been implemented—but have not—then focusing on the cultural side seems the most likely way to achieve a different, better result.

We see several reasons for optimism.

- Citizens’/victims groups have very recently persuaded both the mass media and politicians to take seriously the prevention of valproate exposure during pregnancy. Some of the language from top politicians suggests an underlying cultural shift. The UK’s Health Secretary in February 2018 told the Westminster Parliament that: ‘We must acknowledge that the response to these issues from those in positions of authority has not always been good enough. Sometimes the reaction has felt too focused on defending the status quo.’49

- Scotland’s Chief Medical Officer has been championing the concept of ‘Realistic Medicine’ with widespread national/international agreement and a growing number of examples in practice. 50 This is explicitly a cultural shift based upon six principles, including: ‘shared decision-making’; a ‘whole person approach’; and, ‘better managing risks’. The CMO notes: ‘… just as opinion coalesced around the advent of professionalism in the 19th century, there exists a broad international movement… to co-create health between practitioners and citizens as an inviolable standard.’51

- Scotland’s Minister of Public Health launched an exploration of using devolved powers to ‘go it alone’, if the UK continues to refuse mandatory vitamin B9 fortification. Acknowledging that UK-wide legislation is best, this Minister (and her Welsh counterpart) jointly urged the UK Health Secretary to act in late 2017 and again in 2018.52,53 An earlier Member’s Bill to fortify flour was passed by the House of Lords, but disappeared when the Prime Minister dissolved Parliament for a snap election. 54 A 2018 Westminster debate may revive its prospects. 55

- Particularly in Scotland, modest steps have been taken, and more are underway to prevent, identify and treat...
FASD. These range from the only online NHS course/resource for all professionals on foetal alcohol harm—through the planned 2018 publication on FASD clinical practice from the Scottish Intercollegiate Guidelines Network (SIGN)—to the first recognition of FASD in statutory guidance since Scotland enacted the Additional Support for Learning Act 2004.56,87

- There are Scottish/UK models of building broad coalitions to resolve other key public health issues. These brought together government, voluntary, academic, media and private sectors, as well as individual champions in effective and sustained ways. These successful precedents achieved major changes in culture, law, policy and practice—such as reducing drink driving, the smoking ban and violence reduction (especially knife crime)—and should encourage and inform similar public health efforts around NTDs, FASD and valproate exposure.

- The relevant precedents are not limited to public health, as there is a great deal to learn, and adapt, from other profound social/cultural movements that sparked change. These include lessons from the history of science and medicine, but especially from the women’s rights movement and the children’s rights movement. The whole ’rights’ ethos provides a useful foundation for building both an individual sense of agency and a collective sense of responsibility to prevent harm and promote wellbeing/equity.

Prioritizing preconception health

The biggest still-missing element in overcoming long-standing inaction on these three public health measures is a movement in favour of—and culture changes that give priority to—preconception health, education and care across the life course.58–60 There is an antenatal component to each of the three examples, but they all require much more attention to what happens (or fails to happen) prior to pregnancy.

That, in turn, requires a cultural change beyond the traditional binary choice between either avoiding pregnancy or being pregnant. There are two additional, often-overlooked stages between ‘not pregnant’ and ‘pregnant’. One is being ready, willing and able to make empowered, informed choices about whether and when to become a parent. The other is preparing for pregnancy.51 A society that takes preconception (before the first pregnancy) and interconception (before the next pregnancy) seriously is one in which inaction on NTDs, FASD and valproate would not be tolerated or perpetuated.52

Achieving safer pregnancies and thriving babies is within reach here and now. The key is finally taking robust action on these public health measures. The next generation deserves no less.

Funding

This work was funded by the Scottish Collaboration for Public Health Policy and Research (SCPHRP) core grant from the Medical Research Council (Grant number MR/K023209/1) and the Chief Scientist Office of Scotland. The views expressed in this publication are those of the authors and not necessarily those of the funders. The funders played no role in the conceptualization of the article or in the decision to submit it for publication.

Conflict of interest

The authors declare they have no conflicts of interest.

References

1. Koppaka R. Ten Great Public Health Achievements—Worldwide, 2001–2010. Atlanta: Centers for Disease Control and Prevention (CDC), 2011. https://www.cdc.gov/mmwr/previews/mmwrhtml/mm6024a4.htm (18 June 2018, date last accessed).

2. Vu YA, London WM. Preconception Principle. Oxford: Oxford Bibliographies, 2015. http://www.oxfordbibliographies.com/view/document/obo-9780199756797/obo-9780199756797-0046.xml (18 June 2018, date last accessed).

3. Frank JW, Lomax G. Public health action to control hazards: how good should the evidence be? New Solut 2002;12(1):17–25.

4. Frank JW. Public health policy and the quality of epidemiological evidence: how good is good enough? J Public Health Policy 1985;6(3):313–21.

5. Frank JW, Jepson R, Williams A. Disease Prevention: A Critical Toolkit. Oxford: Oxford University Press, 2015.

6. Glueckman P. The Role of Evidence in Policy Formation and Implementation: A Report From the Prime Minister’s Chief Science Advisor. Auckland: New Zealand Government, 2013. http://www.pmsca.org.nz/wp-content/uploads/The-role-of-evidence-in-policy-formation-and-implementation-report.pdf (18 June 2018, date last accessed).

7. Food Fortification Initiative. Global Progress. Atlanta: FFI Network, 2017. http://www.fifnetwork.org/global_progress/index.php (18 June 2018, date last accessed).

8. Wald N, Sneddon J. Prevention of neural tube defects: results of the Medical Research Council Vitamin Study. Lancet 1991;338(8760):131–37.

9. Cawley S, McCartney D, Woodside Jv. Optimization of folic acid supplementation in the prevention of neural tube defects. J Public Health (Bangkok) 2017;Oct 20:1–8.
10 Turner M, Woodside JV, Cauley S. The Folate Status of Pregnant Women in the Republic of Ireland: The Current Position. Dublin: safefood, 2017. [http://www.safefood.eu/SafeFood/media/SafeFoodLibrary/ Documents/Publications/Research/20Reports/Folate-Status-in-Pregnant-Women-Current-Status-in-Republic-of-Ireland.pdf] (18 June 2018, date last accessed).

11 Kahoshnood B, Loane M, de Walle H. Long term trends in prevalence of neural tube defects in Europe: population based study. Br Med J 2015;351:h5949.

12 Zimmerman SL. Researcher Reflects on Fortification Progress 25 Years After Landmark Study: Interview With Professor Sir Nicholas Wadd. Atlanta: FFI Network, 2016. [http://www.ffinetwork.org/about/ stay_informed/releases/EU_Folic_Acid.html] (18 June 2018, date last accessed).

13 Wald NJ, Morris JK, Blakemore C. Public health failure in the prevention of neural tube defects: time to abandon the tolerable upper intake level of folate. Public Health Rev 2018;39:2.

14 Scientific Advisory Committee on Nutrition (SACN). Update on Folic Acid. London: Public Health England, 2017 [https://www.gov.uk/ government/publications/folic-acid-updated-sacn-recommendations] (18 June 2018, date last accessed).

15 Federation of Bakers. Factsheet No. 24: Flour Fortification. London: FoB UK, 2016. [https://www.fobuk.org/wp-content/uploads/2017/01/Food-Flour-Fortification.pdf] (18 June 2018, date last accessed).

16 Golden J. Message in a Bottle: The Making of Fetal Alcohol Syndrome. Cambridge: Harvard University Press, 2005.

17 Mulherjee R. Review of ‘Message in a Bottle’. Br Med J 2005;331:850.

18 Jones KL, Smith DW. Recognition of the fetal alcohol syndrome in early infancy. Lancet 1973;302:7836:983–1042.

19 Beattie J, Day R, Cockburn F et al. Alcohol and the fetus in the west of Scotland. Br Med J 1983;287:17–20.

20 Sher J. Zika Virus is not the Birth Defect Risk Scotland Should be Most Worried About. Holyrood, 2016. [https://www.holyrood.com/articles/comment/zika-virus-not-birth-defect-risk-scotland-should-be-most-worried-about] (18 June 2018, date last accessed).

21 Benz J, Rasmussen C, Andrew G. Diagnosing fetal alcohol spectrum disorders: history, challenges and future directions. Paediatr Child Health 2009;14(4):231–7.

22 BMA Board of Science. Alcohol and Pregnancy: Preventing and Managing Fetal Alcohol Spectrum Disorders. London: British Medical Association, 2016. [https://www.bma.org.uk/collective-voice/policy-and-research/public-and-population-health/alcohol/alcohol-and-pregnancy] (18 June 2018, date last accessed).

23 Scottish Government. Changing Scotland’s Relationship with Alcohol: A Framework for Action. Edinburgh: Scottish Government, 2009 [http://www.gov.scot/Resource/Doc/262905/0078610.pdf] (18 June 2018, date last accessed).

24 Alcohol Focus Scotland. My Family & Alcohol: Are My Children Affected? Glasgow: AFS, 2018. [http://www.myfamilyandalcohol.org.uk/alcohol-information/my-children/] (18 June 2018, date last accessed).

25 Hope A, Curran J, Bell G. Unrecognized and Under-reported: The Impact of Alcohol on People Other Than the Drinker in Scotland. Glasgow: Alcohol Focus Scotland, 2013. [http://www.alcohol-focus-scotland.org.uk/media/59866/Unrecognised-and-under-reported-full-report.pdf] (18 June 2018, date last accessed).

26 World Health Organization. Global Status Report on Alcohol and Health 2014. Geneva: WHO, 2014. [http://www.who.int/substance_abuse/publications/global_alcohol_report/msb_gsr_2014_1.pdf?ua=1] (18 June 2018, date last accessed).

27 Sher J. Will minimum unit pricing reduce fetal alcohol harm? Int J Birth Parent Educ 2018;5(4):28.

28 Dalens B, Raynaud EJ, Gaulme J. Teratogenicity of valproic acid. J Pediatr 1980;97(2):332–33.

29 Meador KJ. Valproic acid: reducing the risks of pre-natal exposure. Lancet Neurol 2016;15(2):132–3.

30 Medicines and Healthcare products Regulatory Agency (MHRA). Valproate and Risk of Abnormal Pregnancy Outcomes: New Communication Materials. London: UK Government, 2016. [https://www.gov.uk/drug-safety-update/valproate-and-of-risk-of-abnormal-pregnancy-outcomes-new-communication-materials] (18 June 2018, date last accessed).

31 NHS England. Sodium Valproate Prescribing. London: NHS England, 2017. [https://www.england.nhs.uk/publication/prescribing-for-sodium-valproate/] (18 June 2018, date last accessed).

32 Agence nationale de sécurité du medicament et des produits de santé. Strengthening the Prescription and Dispensing Conditions of Valproate and Derived Medicinal Products Due to the Risks Associated With Their Use During Pregnancy. Paris: ANSM, 2017. [http://ansm.sante.fr/content/download/111303/1410275/version/1/file/Enquete-Valproate-Synthese-ANSM.pdf] (3 April 2018, date last accessed).

33 European Medicines Agency. Full EMA Public Hearing on Valproate. London: EMA, 2017. [https://www.youtube.com/watch?v= CxJ5skrGm] (18 June 2018, date last accessed).

34 European Medicines Agency. PR-AC Recommends New Measures to Avoid Valproate Exposure in Pregnancy. London: EMA, 2018. [https://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2018/02/news_detail_002903.jsp&mid=WQ01ac058004d5e1] (18 June 2018, date last accessed).

35 Medicines and Healthcare products Regulatory Agency (MHRA). Valproate Medicines: Contraindicated in Women and Girls of Childbearing Potential Unless Conditions of Pregnancy Prevention Programme are Met. London: UK Government, 2018. [https://www.gov.uk/drug-safety-update/valproate-medicines-epilim-depakote-contraindicated-in-women-and-girls-of-childbearing-potential-unless-conditions-of-pregnancy-prevention-programme-are-met] (18 June 2018, date last accessed).

36 Joint Committee on Health. Report on Foetal Anti-Convulsant Syndrome. Dublin: Houses of the Oireachtas, 2018. [http://opac.oireachtas.ie/AWData/Library3/Joint_Committee_on_Health_Report_on_Foetal_Anti-Convulsant_Syndrome_310518_124838.pdf] (18 June 2018, date last accessed).

37 Sher J. Taking valproate during pregnancy is a serious risk: an update on practice implications. Int J Birth Parent Educ 2018;5(3):11–4.

38 Yi Y, Lindemann M, Colligs A et al. Economic burden of neural tube defects and impact of prevention with folic acid: a literature review. Eur J Pediatr 2011;170(11):1391–1400.
39 Bowles D, Wasia E, Kissner M. Economic burden of neural tube defects in Germany. Public Health 2014;128(3):274–81.
40 Blamont M. France Sets Up Fund for Sanofi Epilepsy Drug Victims. Reuters, 2016. https://www.reuters.com/article/us-sanofi-france-compensation/france-sets-up-fund-for-sanofi-epilepsy-drug-victims-id/USKBN13BIFN (18 June 2018, date last accessed).
41 Perenken CLM, Tahir N, Mahoney EC et al. Prevention of secondary conditions in fetal alcohol spectrum disorders: identification of systems-level barriers. Matern Child Health J 2014;18(6):1496–1505.
42 Poplova S, Lange S, Burd L et al. The economic burden of fetal alcohol spectrum disorder in Canada in 2013. Alcohol Alcohol 2016;51(3):367–75.
43 Sher J. Prevention Means Never Having to Say You’re Sorry. Holyrood, 2017. https://www.holyrood.com/articles/comment/prevention-means-never-having-to-say-youre-sorry (18 June 2018, date last accessed).
44 Christie C, Mitchell J, Wishart R. Commission on the Future Delivery of Public Services. Edinburgh: Scottish Government, 2011. http://www.gov.scot/resource/doc/352649/0118638.pdf (18 June 2018, date last accessed).
45 Carnochan J, Mitchell J, Sher J. Our Prevention Crisis. Holyrood, 2015. https://www.holyrood.com/articles/comment/our-prevention-crisis (18 June 2018, date last accessed).
46 Mercer CH, Tanton C, Prah P. Changes in sexual attitudes and lifestyles in Britain throughout the life course and over time: findings from the National Surveys of Sexual Attitudes and Lifestyles (NATSAL). Lancet 2013;382(9907):1781–94.
47 Information Services Division. Termination of Pregnancy Statistics (Table A: Terminations in Great Britain). Edinburgh: NHS Scotland National Services, 2017. http://www.isdscotland.org/Health-Topics/Sexual-Health/Publications/2017-05-30/2017-05-30-Terminations-2016-Report.pdf (18 June 2018, date last accessed).
48 Moore SJ, Trumppenny P, Quinn A. A clinical study of 57 children with fetal anticonvulsant syndromes. J Med Genet 2000;37:489–97. https://jnpgmj.cmi/content/37/7/489. (18 June 2018, date last accessed).
49 Hunt J. Parliamentary Debate on Medicines Safety Review. London: UK Parliament, 2018. https://hansard.parliament.uk/commons/2018-02-21/debates/7DA2E2F3-E1E6-40CB-8061-680E0399CA97/MedicinesAndMedicalDevicesSafetyReview (18 June 2018, date last accessed).
50 Calderwood C. Realistic Medicine: Chief Medical Officer’s Annual Report 2014-15. Edinburgh: Scottish Government, 2016. http://www.gov.scot/Resource/0049/00492520.pdf (18 June 2018, date last accessed).
51 Calderwood C. Realising Realistic Medicine: Chief Medical Officer’s Annual Report 2015-16. Edinburgh: Scottish Government, 2017. http://www.gov.scot/Resource/0051/00514513.pdf (18 June 2018, date last accessed).
52 de Caestecker I, Sher J. Folic Acid in Breast: Barn Gates and Neural Tubes. Holyrood, 2016. https://www.holyrood.com/articles/comment/folic-acid-bread-barn-gates-and-neural-tubes (18 June 2018, date last accessed).
53 Campbell A, Gething V. Folic Acid in Flour: Joint Letter to the UK Health Secretary. Edinburgh & Cardiff: Scottish and Welsh Governments, 2017. https://news.gov.scot/news/folic-acid-in-flour (18 June 2018, date last accessed).
54 Rooker J. Bread and Flour Regulations (Folic Acid) Bill [HL] 2016-17. UK Parliament, 2017. https://services.parliament.uk/bills/2016-17/breadandflourregulationsfolicacid.html (18 June 2018, date last accessed).
55 UK House of Commons. Fortified Flour. London: Hansard, 2018. https://hansard.parliament.uk/commons/2018-05-16/debates/FDB21E24-2577-4541-A3B5-F06DC69A3B20/FortifiedFlour (18 June 2018, date last accessed).
56 Children in Scotland (Sher J, Collier S). Fetal Alcohol Harm e-Learning Resource. Edinburgh: NHS Education Scotland (The Knowledge Network), 2012. http://uat.knowledge.scot.nhs.uk/home/learning- and-epd/learning-spaces/fasd.aspx (18 June 2018, date last accessed).
57 Scottish Government. Supporting Children’s Learning: Statutory Guidance on the Education (Additional Support for Learning) Act 2004 (as amended) — Code of Practice (3rd edn). Edinburgh: Scottish Government, 2017. http://www.gov.scot/Resource/0052/00529411.pdf (18 June 2018, date last accessed).
58 Sher J. Missed Periods: Scotland’s Opportunities for Better Pregnancies, Healthier Parents and Thriving Babies the First Time... and Every Time. Glasgow: NHS Greater Glasgow and Clyde (Public Health), 2016. http://www.nhsbgg.org.uk/media/237840/missed-periods-j-sher-may-2016.pdf (18 June 2018, date last accessed).
59 Hunter MS. Would you like to become pregnant in the next year?: The One Key Question initiative in the United States. Int J Birth Parent Educ 2017;4(4):19–22.
60 Davies S, Hanson M, Godfrey K. Chapter 5: Preconception Health. The 51% Women—Annual Report of the Chief Medical Officer 2014. London: UK Government, 2015.
61 Verbiest S, advancing preconception health in the United States: strategies for change. Upi J Med Sci 2016;121(4):222–6.
62 Sher J. Making preconception health, education and care real. Int J Birth Parent Educ 2017;4(4):4–8.